Madrigal Pharmaceuticals, Inc. (MDGL)
Madrigal Pharmaceuticals, Inc.
Four Tower Bridge
Suite 200 200 Barr Harbor Drive
West Conshohocken, PA 19428
United States
267 824 2827
https://www.madrigalpharma.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 376
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Rebecca A. Taub M.D. | Founder, Chief Medical Officer, President of Research & Development and Director | 939.83k | N/D | 1952 |
| Mr. Alex G. Howarth | Executive Officer | 757.26k | N/D | 1969 |
| Mr. William J. Sibold | CEO, President & Director | N/D | N/D | 1966 |
| Mr. Ronald Filippo | Chief Information Officer | N/D | N/D | N/D |
| Ms. Tina E. Ventura | Chief Investor Relations Officer | N/D | N/D | N/D |
| Mr. Clint Wallace | Chief Human Resources Officer | N/D | N/D | N/D |
| Mr. Edward Chiang | Senior Vice President of Clinical & Technical Operations | N/D | N/D | N/D |
| Mr. Thomas W. Hare | Senior Vice President of Clinical Management | N/D | N/D | N/D |
| Dr. Robert E. Waltermire Ph.D. | Chief Pharmaceutical Development Officer | N/D | N/D | 1964 |
| Dr. Stephen Dodge M.B.A., Pharm.D. | Senior Vice President of Global Medical Affairs | N/D | N/D | N/D |
Descripción
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.
Gestión corporativa
La calificación ISS Governance QuickScore de Madrigal Pharmaceuticals, Inc. a partir del 29 de abril de 2024 es 8. Las puntuaciones principales son Auditoría: 7; Junta: 9; Derechos del accionista: 8; Compensación: 7.
